Using Virtual Reality and Sensor Technology to Enhance Outcomes From Treatment for Binge Eating
Launched by DREXEL UNIVERSITY · Sep 8, 2021
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
Low levels of inhibitory control (i.e., the ability to withhold a quick, automatic response) is strongly linked with binge eating pathology. One of the most widely used and effective treatments for binge eating leaves 40-60% of patients partially or fully symptomatic at post-treatment. Researchers have begun to investigate the efficacy of computerized inhibitory control trainings (ICTs), which are tasks in which participants are asked repeatedly withhold a keypress responses to food stimuli. The intention of these trainings is to improve inhibitory control and to, in turn, reduce dysregulat...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Speak, write, and understand English
- • Age 18-65 years
- • Experience objectively or subjectively large binge eating episodes once per week or more for the past three months
- • Objectively large binge episodes are defined by the Eating Disorder Examination (EDE; a measure employed in this study) as consisting of at least two full meals of two courses at each (i.e., four courses total) or of at least three main courses
- • Participants, also as per the EDE, must also experience a loss of control over their eating for the given episode to qualify as an objective binge
- • Subjective binges are those which do not meet the food quantity criteria but during which participants experience a loss of control and feel they have eaten too much
- • If applicable, have stable psychiatric medication for the past three months.
- Exclusion Criteria:
- • Acute suicide risk
- • Are planning on receiving psychological treatment for binge eating during the course of their participation in the study
- • Are planning to participate in a structured weight loss treatment program (e.g., WeightWatchers, behavioral weight loss treatment) during the course of their participation in the study
- • Are currently receiving weight loss treatment
- • Have a BMI below 17.5
- • Co-morbid clinically significant psychological disorder that would require attention beyond the study treatment (i.e., bipolar I disorder, substance dependence, and/or psychotic conditions)
- • Diagnosis of intellectual disability or autism spectrum disorder
- • History of neurological condition or traumatic brain injury
- • Current pregnancy or intention to become pregnant during the course of their participation
- • History of bariatric surgery
- • Are currently using a stimulant medication (e.g., Ritalin, Adderall)
- • No internet connection at home
About Drexel University
Drexel University is a prominent research institution located in Philadelphia, Pennsylvania, known for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, Drexel University leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research aimed at improving health outcomes. The university fosters collaborations across various fields, including medicine, engineering, and public health, ensuring a comprehensive approach to addressing complex health challenges. With a focus on ethical standards and participant safety, Drexel University is dedicated to translating research findings into practical applications that enhance community well-being and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Stephanie Manasse, Ph.D.
Principal Investigator
Drexel University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials